Wendy future of retail top

Silarx

Lannett to buy Kremers Urban for $1.23 billion

Lannett to buy Kremers Urban for $1.23 billion

PHILADELPHIA — Lannett Co. plans to acquire Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic drug subsidiary of UCB S.A., in a $1.23 billion deal. Lannett said late Wednesday that the acquisition will add a diversified commercial product portfolio of 18 products. Kremers Urban currently markets generic products that treat a range of conditions, including

PP_1170x120_10-25-21